{"id":"https://openalex.org/W2600769610","doi":"https://doi.org/10.1200/jco.2015.33.15_suppl.2510","title":"ABT-414 in patients with advanced solid tumors likely to overexpress the epidermal growth factor receptor (EGFR).","display_name":"ABT-414 in patients with advanced solid tumors likely to overexpress the epidermal growth factor receptor (EGFR).","publication_year":2015,"publication_date":"2015-05-20","ids":{"openalex":"https://openalex.org/W2600769610","doi":"https://doi.org/10.1200/jco.2015.33.15_suppl.2510","mag":"2600769610"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2015.33.15_suppl.2510","doi":"https://doi.org/10.1200/jco.2015.33.15_suppl.2510","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2015.33.15_suppl.2510","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5009677422","display_name":"Glenwood D. Goss","orcid":"https://orcid.org/0000-0002-5316-1022","observed_orcids":["https://orcid.org/0000-0002-5316-1022"]},"institutions":[{"id":"https://openalex.org/I2800722420","display_name":"Ottawa Hospital","ror":"https://ror.org/03c62dg59","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I2800722420"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Glenwood D. Goss","raw_affiliation_strings":["The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada","institution_ids":["https://openalex.org/I2800722420"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063904421","display_name":"Everett E. Vokes","orcid":"https://orcid.org/0000-0002-8645-8068","observed_orcids":["https://orcid.org/0000-0002-8645-8068"]},"institutions":[{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Everett E. Vokes","raw_affiliation_strings":["University of Chicago, Chicago, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Chicago, Chicago, IL","institution_ids":["https://openalex.org/I40347166"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069690249","display_name":"Michael S. Gordon","orcid":"https://orcid.org/0000-0002-7679-9504","observed_orcids":["https://orcid.org/0000-0002-7679-9504"]},"institutions":[{"id":"https://openalex.org/I4210146652","display_name":"Pinnacle Oncology Hematology","ror":"https://ror.org/043rqx383","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210146652"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael S. Gordon","raw_affiliation_strings":["Pinnacle Oncology Hematology, Scottsdale, AZ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pinnacle Oncology Hematology, Scottsdale, AZ","institution_ids":["https://openalex.org/I4210146652"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020504047","display_name":"Leena Gandhi","orcid":"https://orcid.org/0000-0002-2398-9179","observed_orcids":["https://orcid.org/0000-0002-2398-9179"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Leena Gandhi","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022467575","display_name":"Kyriakos P. Papadopoulos","orcid":"https://orcid.org/0000-0002-0667-2620","observed_orcids":["https://orcid.org/0000-0002-0667-2620"]},"institutions":[{"id":"https://openalex.org/I4210119066","display_name":"South Texas Accelerated Research Therapeutics","ror":"https://ror.org/01scs7915","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210119066"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kyriakos P. Papadopoulos","raw_affiliation_strings":["South Texas Accelerated Research Therapeutics, San Antonio, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"South Texas Accelerated Research Therapeutics, San Antonio, TX","institution_ids":["https://openalex.org/I4210119066"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073134832","display_name":"Drew Warren Rasco","orcid":"https://orcid.org/0009-0009-6619-2854","observed_orcids":["https://orcid.org/0009-0009-6619-2854"]},"institutions":[{"id":"https://openalex.org/I4210119066","display_name":"South Texas Accelerated Research Therapeutics","ror":"https://ror.org/01scs7915","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210119066"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Drew Warren Rasco","raw_affiliation_strings":["South Texas Accelerated Research Therapeutics, San Antonio, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"South Texas Accelerated Research Therapeutics, San Antonio, TX","institution_ids":["https://openalex.org/I4210119066"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025845614","display_name":"Michelle Pedersen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2948539688","display_name":"AbbVie (United States)","ror":"https://ror.org/02g5p4n58","country_code":"US","type":"company","lineage":["https://openalex.org/I2948539688"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michelle Pedersen","raw_affiliation_strings":["AbbVie Inc., North Chicago, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AbbVie Inc., North Chicago, IL","institution_ids":["https://openalex.org/I2948539688"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040390187","display_name":"Judee S. Fischer","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2948539688","display_name":"AbbVie (United States)","ror":"https://ror.org/02g5p4n58","country_code":"US","type":"company","lineage":["https://openalex.org/I2948539688"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Judee S. Fischer","raw_affiliation_strings":["AbbVie Inc., North Chicago, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AbbVie Inc., North Chicago, IL","institution_ids":["https://openalex.org/I2948539688"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5105523962","display_name":"Katharine L. Chu","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2948539688","display_name":"AbbVie (United States)","ror":"https://ror.org/02g5p4n58","country_code":"US","type":"company","lineage":["https://openalex.org/I2948539688"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Katharine Chu","raw_affiliation_strings":["AbbVie Inc., North Chicago, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AbbVie Inc., North Chicago, IL","institution_ids":["https://openalex.org/I2948539688"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013790282","display_name":"William Ames","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2948539688","display_name":"AbbVie (United States)","ror":"https://ror.org/02g5p4n58","country_code":"US","type":"company","lineage":["https://openalex.org/I2948539688"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"William Ames","raw_affiliation_strings":["AbbVie Inc., North Chicago, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AbbVie Inc., North Chicago, IL","institution_ids":["https://openalex.org/I2948539688"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016906085","display_name":"Hao Xiong","orcid":"https://orcid.org/0000-0001-6222-426X","observed_orcids":["https://orcid.org/0000-0001-6222-426X"]},"institutions":[{"id":"https://openalex.org/I2948539688","display_name":"AbbVie (United States)","ror":"https://ror.org/02g5p4n58","country_code":"US","type":"company","lineage":["https://openalex.org/I2948539688"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hao Xiong","raw_affiliation_strings":["AbbVie Inc., North Chicago, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AbbVie Inc., North Chicago, IL","institution_ids":["https://openalex.org/I2948539688"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100725156","display_name":"Ho\u2010Jin Lee","orcid":"https://orcid.org/0000-0002-7134-5044","observed_orcids":["https://orcid.org/0000-0002-7134-5044"]},"institutions":[{"id":"https://openalex.org/I2948539688","display_name":"AbbVie (United States)","ror":"https://ror.org/02g5p4n58","country_code":"US","type":"company","lineage":["https://openalex.org/I2948539688"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ho-Jin Lee","raw_affiliation_strings":["AbbVie Inc., North Chicago, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AbbVie Inc., North Chicago, IL","institution_ids":["https://openalex.org/I2948539688"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112640310","display_name":"Jiewei Zeng","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2948539688","display_name":"AbbVie (United States)","ror":"https://ror.org/02g5p4n58","country_code":"US","type":"company","lineage":["https://openalex.org/I2948539688"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jiewei Zeng","raw_affiliation_strings":["AbbVie Inc., North Chicago, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AbbVie Inc., North Chicago, IL","institution_ids":["https://openalex.org/I2948539688"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046267092","display_name":"Lisa A. Roberts-Rapp","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2948539688","display_name":"AbbVie (United States)","ror":"https://ror.org/02g5p4n58","country_code":"US","type":"company","lineage":["https://openalex.org/I2948539688"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lisa Roberts-Rapp","raw_affiliation_strings":["AbbVie Inc., North Chicago, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AbbVie Inc., North Chicago, IL","institution_ids":["https://openalex.org/I2948539688"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033578335","display_name":"Peter J. Ansell","orcid":"https://orcid.org/0000-0002-4088-2840","observed_orcids":["https://orcid.org/0000-0002-4088-2840"]},"institutions":[{"id":"https://openalex.org/I2948539688","display_name":"AbbVie (United States)","ror":"https://ror.org/02g5p4n58","country_code":"US","type":"company","lineage":["https://openalex.org/I2948539688"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Peter Ansell","raw_affiliation_strings":["AbbVie, North Chicago, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AbbVie, North Chicago, IL","institution_ids":["https://openalex.org/I2948539688"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055289962","display_name":"Ed Reilly","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2948539688","display_name":"AbbVie (United States)","ror":"https://ror.org/02g5p4n58","country_code":"US","type":"company","lineage":["https://openalex.org/I2948539688"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ed Reilly","raw_affiliation_strings":["AbbVie Inc., North Chicago, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AbbVie Inc., North Chicago, IL","institution_ids":["https://openalex.org/I2948539688"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015092618","display_name":"Kyle D. Holen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2948539688","display_name":"AbbVie (United States)","ror":"https://ror.org/02g5p4n58","country_code":"US","type":"company","lineage":["https://openalex.org/I2948539688"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kyle D. Holen","raw_affiliation_strings":["AbbVie Inc., North Chicago, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AbbVie Inc., North Chicago, IL","institution_ids":["https://openalex.org/I2948539688"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5060992997","display_name":"Anthony W. Tolcher","orcid":"https://orcid.org/0000-0002-6322-9721","observed_orcids":["https://orcid.org/0000-0002-6322-9721"]},"institutions":[{"id":"https://openalex.org/I4210119066","display_name":"South Texas Accelerated Research Therapeutics","ror":"https://ror.org/01scs7915","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210119066"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Anthony W. Tolcher","raw_affiliation_strings":["South Texas Accelerated Research Therapeutics, San Antonio, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"South Texas Accelerated Research Therapeutics, San Antonio, TX","institution_ids":["https://openalex.org/I4210119066"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":6,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":5,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"33","issue":"15_suppl","first_page":"2510","last_page":"2510"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.7534000277519226,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.7534000277519226,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.22990000247955322,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":0.003599999938160181,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/abt-414","display_name":"ABT-414","score":0.9990000128746033},{"id":"https://openalex.org/keywords/egfr","display_name":"EGFR","score":0.5170000195503235},{"id":"https://openalex.org/keywords/antibody-drug-conjugates","display_name":"antibody-drug conjugates","score":0.8740000128746033},{"id":"https://openalex.org/keywords/egfrviii","display_name":"EGFRvIII","score":0.8009999990463257},{"id":"https://openalex.org/keywords/egfr-amplification","display_name":"EGFR amplification","score":0.8320000171661377},{"id":"https://openalex.org/keywords/advanced-solid-tumors","display_name":"advanced solid tumors","score":0.9300000071525574},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.9459999799728394},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.9120000004768372},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.7129999995231628},{"id":"https://openalex.org/keywords/antitumor-efficacy","display_name":"antitumor efficacy","score":0.6169999837875366},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.33500000834465027}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8851981163024902},{"id":"https://openalex.org/C72563966","wikidata":"https://www.wikidata.org/wiki/Q1303415","display_name":"Cohort","level":2,"score":0.599205732345581},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5962797999382019},{"id":"https://openalex.org/C2780580376","wikidata":"https://www.wikidata.org/wiki/Q186889","display_name":"Nausea","level":2,"score":0.5589134097099304},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5545158982276917},{"id":"https://openalex.org/C2779438470","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"Epidermal growth factor receptor","level":3,"score":0.5076807737350464},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.46902361512184143},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4632965326309204},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.4622926414012909},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3526753783226013}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2015.33.15_suppl.2510","doi":"https://doi.org/10.1200/jco.2015.33.15_suppl.2510","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2015.33.15_suppl.2510","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2127320503","https://openalex.org/W1982244230","https://openalex.org/W2290428590","https://openalex.org/W1995793475","https://openalex.org/W2644550223","https://openalex.org/W2341507734","https://openalex.org/W2793831611","https://openalex.org/W2324460788","https://openalex.org/W2531668987","https://openalex.org/W3029672551"],"abstract_inverted_index":{"2510":[0],"Background:":[1],"Aberrant":[2],"EGFR":[3,164],"expression":[4],"and":[5,16,59,79,123,140,159,205,222,261,333],"signaling":[6],"has":[7,40],"been":[8],"identified":[9],"as":[10],"a":[11,246],"hallmark":[12],"of":[13,24,61,86,109,131,279,284,308,315],"cancer":[14],"growth":[15],"survival.":[17],"ABT-414":[18,39,62,74,110,150,157,174,270,285,316],"is":[19,318],"an":[20,83],"antibody-drug":[21],"conjugate":[22],"composed":[23],"the":[25,34,55,73,93,132,134,141,145,152,228,259,262,272,292],"antibody":[26,275],"ABT-806,":[27],"targeting":[28],"active":[29],"EGFR/mutant":[30],"EGFRvIII,":[31],"linked":[32],"to":[33,154,163,197,239,257,287],"anti-microtubule":[35],"agent":[36],"monomethylauristatin":[37],"F.":[38],"shown":[41],"potent":[42],"antitumor":[43,331],"activity":[44,332],"in":[45,63,82,112,245,306,325,337],"several":[46,240],"EGFR-overexpressing":[47],"tumor":[48],"xenografts.":[49],"This":[50],"phase":[51,136],"1/2":[52],"trial":[53,342],"evaluates":[54],"safety,":[56,129],"pharmacokinetics":[57],"(PK),":[58],"efficacy":[60,81,161,323],"patients":[64],"(pts)":[65],"with":[66,88,101,276,327],"solid":[67,104],"tumors":[68,105,329],"(NCT01741727).":[69],"Herein,":[70],"we":[71],"report":[72],"maximum":[75],"tolerated":[76],"dose":[77,138,254,289],"(MTD)":[78],"preliminary":[80,160,322],"expanded":[84],"cohort":[85],"pts":[87,96,148,172,310,326],"EGFR-amplified":[89,146,180,293,328],"tumors.":[90],"Methods:":[91],"In":[92,144,291],"dose-escalation":[94],"cohorts,":[95,176],"(":[97],"\u2265":[98],"18":[99],"years)":[100],"advanced":[102],"EGFR+":[103],"received":[106,149,173],"escalating":[107],"doses":[108],"intravenously":[111],"2":[113,137,235],"schedules,":[114],"either":[115],"on":[116,120],"day":[117],"1":[118,122,233,295],"or":[119],"days":[121],"8":[124],"Q3W.":[125,269],"Primary":[126],"objectives":[127],"included":[128],"determination":[130],"MTD,":[133],"recommended":[135],"(RP2D),":[139],"PK":[142,282],"profile.":[143],"cohort,":[147,181,294],"at":[151,234,250,266],"MTD":[153,260],"further":[155,335],"assess":[156],"safety":[158],"related":[162],"expression.":[165],"Results:":[166],"By":[167],"15":[168],"Dec":[169],"2014,":[170],"53":[171,309],"(dose-escalation":[175],"n":[177,182],"=":[178,183,232],"48;":[179],"5).":[184],"Most":[185,209],"common":[186,210],"treatment-emergent":[187],"adverse":[188],"events":[189],"(TEAEs)":[190],"were":[191,214],"blurred":[192,217],"vision":[193,218],"(49%,":[194],"commonly":[195],"due":[196],"transient":[198],"microcystic":[199],"keratopathy),":[200],"fatigue":[201],"(42%),":[202,204],"nausea":[203],"dry":[206],"eyes":[207],"(36%).":[208],"grade":[211,241],"3/4":[212],"TEAEs":[213,244],"keratitis":[215],"(8%),":[216],"(6%),":[219,221],"dyspnea":[220],"hyponatremia":[223],"(6%).":[224],"Eye":[225],"pain":[226],"was":[227,255,264,271,298],"only":[229],"DLT":[230],"(n":[231],"mg/kg":[236,268],"Q3W).":[237],"Due":[238],"3":[242,267,319],"ophthalmologic":[243],"single":[247],"pt":[248],"treated":[249],"4.0":[251],"mg/kg,":[252],"this":[253,338],"considered":[256],"exceed":[258],"RP2D":[263,314],"set":[265],"predominant":[273],"circulating":[274],"low":[277],"levels":[278],"unconjugated":[280],"ABT-806.":[281],"exposure":[283],"appeared":[286],"be":[288],"proportional.":[290],"partial":[296],"response":[297],"observed":[299,324],"(triple-negative":[300],"breast":[301],"cancer).":[302],"Stable":[303],"disease":[304],"occurred":[305],"11":[307],"(21%).":[311],"Conclusions:":[312],"The":[313,321],"(Q3W)":[317],"mg/kg.":[320],"suggests":[330],"warrants":[334],"investigation":[336],"select":[339],"population.":[340],"Clinical":[341],"information:":[343],"NCT01741727.":[344]},"counts_by_year":[{"year":2018,"cited_by_count":1},{"year":2017,"cited_by_count":2},{"year":2016,"cited_by_count":2}],"updated_date":"2026-09-22T06:50:58.402377","created_date":"2017-04-07T00:00:00"}